TRT injections vs testosterone pellets.

Before comparing delivery methods, the diagnosis has to be solid. Testosterone deficiency requires consistent symptoms plus at least two morning total testosterone measurements below the reference range, drawn fasting on separate days. Testosterone follows a daily rhythm and drops after eating — an afternoon draw after lunch is not a diagnosis.

A proper workup also includes free testosterone with SHBG, LH and FSH to distinguish primary from secondary hypogonadism, prolactin, estradiol, a CBC for baseline hematocrit, a metabolic panel, and PSA in men over 40. Low testosterone can be a symptom of something else — obesity, sleep apnea, opioid use, thyroid disease, or a pituitary problem — and treating the number without asking why is poor medicine.

Pellets and frequent injections both deliver steady levels. The difference is what happens when the dose is wrong.

With injections, a hematocrit creeping toward 54%, an estradiol rise, or a level far above target can be corrected within a week. With pellets, you wait out the cycle. For a first-time patient whose optimal dose is unknown, that argues for starting on injections or cream, establishing the right dose over three to six months, and switching to pellets afterward for convenience if the patient prefers it.

Pellets suit the man who has been stable for a year, hates needles, travels constantly, or has repeatedly fallen off a daily or weekly protocol. Convenience that gets used beats precision that gets abandoned.

Fertility. All forms of exogenous testosterone suppress LH and FSH and can substantially reduce sperm production — often to zero. Any man who may want children should discuss hCG, clomiphene, or enclomiphene as alternatives or adjuncts before starting, and should bank sperm if uncertain.

Monitoring. Guidelines call for checking testosterone and hematocrit at three to six months, then annually, with PSA monitoring in men over 40. Erythrocytosis is the most common dose-related adverse effect; a hematocrit above 54% requires dose reduction or therapeutic phlebotomy.

Cardiovascular safety. The TRAVERSE trial, a large randomized cardiovascular outcomes study published in 2023, found testosterone therapy noninferior to placebo for major adverse cardiac events in middle-aged and older men with hypogonadism and elevated cardiovascular risk. It did observe higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury — worth discussing individually.

Testosterone alone is not a plan. Lean mass, strength, and metabolic improvement require protein and resistance training alongside the therapy. See why muscle loss accelerates after 40.

We ask four questions: Do you want children in the next five years? Will you reliably do something weekly? Is your baseline hematocrit already high? And how much does clinic frequency matter to your schedule?

Most men start on weekly or twice-weekly subcutaneous injections while we find the dose, then choose. Roughly half stay on injections for the control and cost; the rest move to pellets once stable. Either way, the labs and the recheck schedule are the same. Learn more about our approach to men's health.